StockData
Artiva Biotherapeutics, Inc. logo

Artiva Biotherapeutics, Inc. (ARTV) stock

ARTVNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 9, 2026Score 8/30
$3.78−0.05 (-1.31%)

Close on Nov 20, 2026Market cap $184.81MP/E –Yield –

Artiva Biotherapeutics free cash flow

Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.

Artiva Biotherapeutics's free cash flow for the twelve months ending Jun 30, 2026 was -$76.91M. For fiscal 2025 it was -$79.34M.

Annual free cash flow

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$79.34M–
FY2024Dec 31, 2024-$55.67M–
FY2023Dec 31, 2023-$50.69M–

Quarterly free cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$20.77M–
Q1 FY2026Mar 31, 2026-$21.19M–
Q4 FY2025Dec 31, 2025-$15.15M–
Q3 FY2025Sep 30, 2025-$19.80M–
Q2 FY2025Jun 30, 2025-$24.04M–
Q1 FY2025Mar 31, 2025-$20.35M–
Q4 FY2024Dec 31, 2024-$14.71M–
Q3 FY2024Sep 30, 2024-$11.71M–
Q2 FY2024Jun 30, 2024-$14.15M–
Q1 FY2024Mar 31, 2024-$15.10M–
Q4 FY2023Dec 31, 2023-$11.31M–
Q3 FY2023Sep 30, 2023-$10.93M–

More Artiva Biotherapeutics figures

See a number that looks wrong?